YUNNAN BAIYAO(SZ:000538)2026-01-27 09:06Group 1: AI Empowerment and Digital Transformation - The company is implementing its digital development plan (2022-2026) by leveraging data and AI technologies across key segments of the supply chain, enhancing operational efficiency and business innovation [2] - The self-developed "Marketing Business Operation Platform" has been piloted in the pharmaceutical business group, improving order processing and cost accounting, leading to a 30% reduction in manual workload and saving 60,000 paper documents annually [3] - The "One Product, One Code Traceability Platform" has been developed for traditional Chinese medicine, providing digital identity for authentic medicinal materials [2] Group 2: Supply Chain and Operational Efficiency - The company has achieved 100% automation in settlement processes, reducing the cycle from 30 days to real-time [3] - The establishment of 90 standard processes and 60 management indicators supports business decision-making effectively [3] - The "Smart Cloud Medicine" platform and "One Product, One Chain" model have created a closed-loop system covering all aspects from resource management to payment, significantly improving supply chain collaboration and management [3] Group 3: Research and Development Progress - The tumor organ library and molecular marker research projects have yielded results published in Cancer Cell and Chinese Clinical Oncology journals [4] - The INR101 diagnostic nuclear medicine project has entered phase III clinical trials, with 32 research centers established and 60 subjects enrolled [5] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with phase I trials initiated and 12 patients enrolled [6] Group 4: Dividend Distribution - For the 2024 fiscal year, the company will distribute a cash dividend of 11.85 CNY per 10 shares, totaling 2,164,310,537.44 CNY, which represents 90.09% of the net profit attributable to shareholders [7] - The total cash dividend for 2024, including a special dividend, amounts to 23.98 CNY per 10 shares, with a total of 4,278,661,722.00 CNY distributed [7] - In the first half of 2025, a cash dividend of 10.19 CNY per 10 shares will be distributed, totaling 1.818 billion CNY, representing 50.05% of the net profit for that period [7] Group 5: Online Sales Performance - The pharmaceutical business group has seen over a 20% increase in O2O sales in the first half of 2025, aided by online content marketing [8] - The company generated 2.54 billion CNY in GMV from e-commerce platforms, attracting 4.845 million visitors and converting 3.54 million consumers [9] - Yunnan Baiyao toothpaste holds the number one market share in the domestic channel for 2025, while the brand ranked first in Tmall for anti-hair loss shampoo during the "618" shopping festival [9]